Headache classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38:1–211. https://doi.org/10.1177/0333102417738202

Article  Google Scholar 

GBD 2016 Disease and Injury Incidence and Prevalence Collaborators (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet 390:1211–1259. https://doi.org/10.1016/s0140-6736(17)32154-2

Yao C, Wang Y, Wang L, Liu Y, Liu J, Qi J et al (2019) Burden of headache disorders in China, 1990-2017: findings from the global burden of disease study 2017. J Headache Pain 20:102. https://doi.org/10.1186/s10194-019-1048-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abu Bakar N, Tanprawate S, Lambru G, Torkamani M, Jahanshahi M, Matharu M (2016) Quality of life in primary headache disorders: a review. Cephalalgia 36:67–91. https://doi.org/10.1177/0333102415580099

Article  PubMed  Google Scholar 

Blumenfeld A, Varon S, Wilcox T, Buse D, Kawata A, Manack A et al (2011) Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the international burden of migraine study (IBMS). Cephalalgia 31:301–315. https://doi.org/10.1177/0333102410381145

Article  CAS  PubMed  Google Scholar 

Shimizu T, Sakai F, Miyake H, Sone T, Sato M, Tanabe S et al (2021) Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. J Headache Pain 22:29. https://doi.org/10.1186/s10194-021-01243-5

Article  PubMed  PubMed Central  Google Scholar 

Buse DC, Nahas SJ, Stewart WBF, Armand CE, Reed ML, Fanning KM et al (2023) Optimized acute treatment of migraine is associated with greater productivity in people with migraine: results from the chronic migraine epidemiology and outcomes (CaMEO) study. J Occup Environ Med 65:e261–e268. https://doi.org/10.1097/jom.0000000000002801

Article  PubMed  PubMed Central  Google Scholar 

Zhao H, Xiao Z, Zhang L, Ford J, Zhong S, Ye W et al (2023) Real-world treatment patterns and outcomes among patients with episodic migraine in China: results from the Adelphi migraine disease specific Programme™. J Pain Res 16:357–371. https://doi.org/10.2147/jpr.S371887

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang X, Xing Y, Sun J, Zhou H, Yu H, Zhao Y et al (2016) Prevalence, associated factors, and impact on quality of life of migraine in a Community in Northeast China. J Oral Facial Pain Headache 30:139–149. https://doi.org/10.11607/ofph.1584

Article  PubMed  Google Scholar 

Raffaelli B, Rubio-Beltrán E, Cho SJ, De Icco R, Labastida-Ramirez A, Onan D et al (2023) Health equity, care access and quality in headache - part 2. J Headache Pain 24:167. https://doi.org/10.1186/s10194-023-01699-7

Article  PubMed  PubMed Central  Google Scholar 

Martelletti P, Leonardi M, Ashina M, Burstein R, Cho SJ, Charway-Felli A et al (2023) Rethinking headache as a global public health case model for reaching the SDG 3 HEALTH by 2030. J Headache Pain 24:140. https://doi.org/10.1186/s10194-023-01666-2

Article  PubMed  PubMed Central  Google Scholar 

Li X, Zhou J, Tan G, Wang Y, Ran L, Chen L (2012) Diagnosis and treatment status of migraine: a clinic-based study in China. J Neurol Sci 315:89–92. https://doi.org/10.1016/j.jns.2011.11.021

Article  PubMed  Google Scholar 

Liu H, Dong M, Liu K, Jia Z, Gui W, Cheng Y et al (2023) Status of diagnosis and preventative treatment for primary headache disorders: real-world data of unmet needs in China. J Headache Pain 24:119. https://doi.org/10.1186/s10194-023-01654-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu S, Zhang M, Zhou J, Liu R, Wan Q, Li Y (2014) Headache care in China. Headache 54:601–609. https://doi.org/10.1111/head.12330

Article  PubMed  Google Scholar 

Liu R, Yu S, He M, Zhao G, Yang X, Qiao X et al (2013) Health-care utilization for primary headache disorders in China: a population-based door-to-door survey. J Headache Pain 14:47. https://doi.org/10.1186/1129-2377-14-47

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu S, Zhang Y, Yao Y, Cao H (2020) Migraine treatment and healthcare costs: retrospective analysis of the China health insurance research association (CHIRA) database. J Headache Pain 21:53. https://doi.org/10.1186/s10194-020-01117-2

Article  PubMed  PubMed Central  Google Scholar 

Chinese Medical Association Group (2022) Guidelines for Diagnosis and Treatment of Migraine in China (2022 Edition). Chin J Pain Med 28:881–898

Ailani J, Burch RC, Robbins MS, on behalf of the Board of Directors of the American Headache Society (2021) The American headache society consensus statement: update on integrating new migraine treatments into clinical practice. Headache 61:1021–1039. https://doi.org/10.1111/head.14153

Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A et al (2009) EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol 16:968–981. https://doi.org/10.1111/j.1468-1331.2009.02748.x

Article  CAS  PubMed  Google Scholar 

Marmura MJ, Silberstein SD, Schwedt TJ (2015) The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 55:3–20. https://doi.org/10.1111/head.12499

Article  PubMed  Google Scholar 

Hutchinson S, Lipton RB, Ailani J, Reed ML, Fanning KM, Adams AM et al (2020) Characterization of acute prescription migraine medication use: results from the CaMEO study. Mayo Clin Proc 95:709–718. https://doi.org/10.1016/j.mayocp.2019.11.025

Article  PubMed  Google Scholar 

Lipton RB, Munjal S, Alam A, Buse DC, Fanning KM, Reed ML et al (2018) Migraine in America symptoms and treatment (MAST) study: baseline study methods, treatment patterns, and gender differences. Headache. 58:1408–1426. https://doi.org/10.1111/head.13407

Article  PubMed  Google Scholar 

Roessler T, Zschocke J, Roehrig A, Friedrichs M, Friedel H, Katsarava Z (2020) Administrative prevalence and incidence, characteristics and prescription patterns of patients with migraine in Germany: a retrospective claims data analysis. J Headache Pain 21:85. https://doi.org/10.1186/s10194-020-01154-x

Article  PubMed  PubMed Central  Google Scholar 

Vo P, Paris N, Bilitou A, Valena T, Fang J, Naujoks C et al (2018) Burden of migraine in Europe using self-reported digital diary data from the migraine buddy© application. Neurol Ther 7:321–332. https://doi.org/10.1007/s40120-018-0113-0

Article  PubMed  PubMed Central  Google Scholar 

Lyu S, Zhang CS, Sun J, Weng H, Xue CC, Guo X et al (2022) Chinese herbal medicine for migraine management: a hospital-based retrospective analysis of electronic medical records. Front Med (Lausanne) 9:936234. https://doi.org/10.3389/fmed.2022.936234

Article  PubMed  Google Scholar 

Dodick DW, Shewale AS, Lipton RB, Baum SJ, Marcus SC, Silberstein SD et al (2020) Migraine patients with cardiovascular disease and contraindications: an analysis of real-world claims data. J Prim Care Community Health 11:2150132720963680. https://doi.org/10.1177/2150132720963680

Article  PubMed  PubMed Central  Google Scholar 

Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA (2007) Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 115:1634–1642. https://doi.org/10.1161/circulationaha.106.181424

Article  PubMed  Google Scholar 

Cooper W, Doty EG, Hochstetler H, Hake A, Martin V (2020) The current state of acute treatment for migraine in adults in the United States. Postgrad Med 132:581–589. https://doi.org/10.1080/00325481.2020.1767402

Article  PubMed  Google Scholar 

Dong Z, Chen X, Steiner TJ, Hou L, Di H, He M et al (2015) Medication-overuse headache in China: clinical profile, and an evaluation of the ICHD-3 beta diagnostic criteria. Cephalalgia 35:644–651. https://doi.org/10.1177/0333102414552533

Article  PubMed  Google Scholar 

Zhang L, Novick D, Zhong S, Li J, Walker C, Harrison L et al (2023) Real-world analysis of clinical characteristics, treatment patterns, and patient-reported outcomes of insufficient responders and responders to prescribed acute migraine treatment in China. Pain Ther. https://doi.org/10.1007/s40122-023-00494-1

Lipton RB, Fanning KM, Serrano D, Reed ML, Cady R, Buse DC (2015) Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology 84:688–695. https://doi.org/10.1212/wnl.0000000000001256

Article  PubMed  PubMed Central  Google Scholar 

Luo N, Qi W, Zhuang C, Di W, Lu Y, Huang Z et al (2014) A satisfaction survey of current medicines used for migraine therapy in China: is Chinese patent medicine effective compared with Western medicine for the acute treatment of migraine? Pain Med 15:320–328. https://doi.org/10.1111/pme.12277

Article  PubMed  Google Scholar 

Edvinsson L (2019) Role of CGRP in migraine. Handb Exp Pharmacol 255:121–130. https://doi.org/10.1007/164_2018_201

Article  CAS  PubMed  Google Scholar 

Monthly Report: New Drug Approvals in China, September 2023 (2023). https://baipharm.chemlinked.com/news/monthly-report-new-drug-approvals-in-china-september-2023. Accessed October 9 2023

Nurtec ODT (rimegepant) Prescribing information. https://labeling.pfizer.com/ShowLabeling.aspx?id=19036. Accessed May 12 2023

Vydura (Rimegepant) Prescribing Information. https://www.pfizerpro.co.uk/medicine/vydura. Accessed 2023 May 12

Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M et al (2019) Rimegepant, an Oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med 381:142–149. https://doi.org/10.1056/NEJMoa1811090

Article  CAS  PubMed  Google Scholar 

Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG et al (2019) Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet 394:737–745. https://doi.org/10.1016/S0140-6736(19)31606-X

Article  CAS  PubMed